Calendario›REGN›ALN-CIDEB

ALN-CIDEB

Study to Evaluate ALN-CIDEB in Adults With Fibrotic Metabolic Dysfunction-Associated Steatohepatitis (MASH)

Ensayo de REGENERON PHARMACEUTICALS, INC. en Metabolic Dysfunction-Associated Steatohepatitis (MASH) (del registro, en inglés).

Fase

Fase 2

Estado

Aún sin reclutar

Participantes

150

previstos

Fin del objetivo primario

feb 2029

estimado por el promotor

Qué significa cada fase y cada estado.

Estudio de intervención, aleatorizado, cuádruple ciego. Comenzó en jul 2026.

Qué mide

Percent change from baseline in liver fat by Magnetic Resonance Imaging-derived Proton Density Fat Fraction (MRI-PDFF) (del registro, en inglés) (en la semana 26)

Cómo lo describe el promotor

En el documentoEn inglés, del registroThis study will test a Regeneron study drug called ALN-CIDEB to find out whether it may help treat a liver disease called MASH. In this study, researchers are looking at the effect of ALN-CIDEB on reducing liver fat, liver injury, and liver scarring. The study will compare ALN-CIDEB with placebo to understand how well ALN-CIDEB works to lower the amount of fat in the liver. The study is looking at: * What side effects ALN-CIDEB might cause * How well ALN-CIDEB works to change liver fat, liver injury, and liver scarring * How the body and the liver change after having ALN-CIDEB, which can help researchers understand why ALN-CIDEB works better for some people than others

Más ensayos de REGN

Todos los de REGN, en su ficha.

Ficha completa en ClinicalTrials.gov (NCT07631637), actualizada en jun 2026.